Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D; community with critical information on the tools, technologies, and trends that drive the biotech industry.
Issue link: http://gen.epubxp.com/i/729777
50 | OCTOBER 1, 2016 | GENengnews.com | Genetic Engineering & Biotechnology News CORPORATE CAPABILITIES Advertorial OriGene 9620 Medical Center Drive, Suite 200 Rockville, MD 20850 Phone 888.267.4436 Website www.origene.com Date Founded 1996 Number of Employees 500 OriGene Technologies Evolving from a Gene-Based Tool Provider to a Premier Antibody Supplier, for Both Research and Diagnostic Fields O riGene Technologies was founded in 1996 as a research tool com- pany focused on the creation of the largest commercial collection of full length human cDNAs in a standard expression vector. OriGene's mission, to prepare comprehensive sets of gene re- search tools and technology plat- forms, has enabled scientists to study complete biological path- ways, thus facilitating a better und ways, thus facilitating a better understanding of biological processes and disease regulation. biological processes and disease regulation. The The biological processes and disease regulation. The comprehensive expression clone is the core asset of OriGene. Upon this foundation, the company has prepared 17,000 over-expression cell lysates, 10,000 purified recombinant human proteins from HEK293 cells, and 8,000 highly character- ized TrueMAB™ monoclonal antibodies. Over the past few years, OriGene has strate- gically integrated multiple technologies through corporate acquisitions to create whole-product solutions for biomedical and clinical research- ers. The OriGene family now includes Cytomyx, Marligen Biosciences, and Blue Heron (a leader in gene synthesis services). The recent acquisitions of ZSbio (a leading Chinese pathology company) and SDIX mark the company's latest venture into the anatomic pathology and IVD market. Markets Served 1. Molecular Biology As "Your Gene Company," OriGene has a broad portfolio of biological reagents and services that are of value to both academic research and industry product development. Utilizing high-throughput technologies in mo- lecular cloning, the human cDNA collection is nearing completion with respect to the NCBI RefSeq curated database of unique human transcripts. Such a comprehensive portfolio of cDNA clones is of particular value to labora- tories tories that wish to move their projects along that tories that wish to move their projects along wish tories that wish to move their projects along to tories that wish to move their projects along move their tories that wish to move their projects along quickly by purchasing ready quickly by purchasing ready-made clones and where time is of the essen and where time is of the essence in mission critical research. If not immedia critical research. If not immediately available, OriGene's Blue Heron synthes OriGene's Blue Heron synthesis service can conveniently provide any gene, conveniently provide any gene, any sequence, in any vector, with add-on services in any vector, with add-on services of codon- of in any vector, with add-on services of codon- codon- in any vector, with add-on services of codon- optimization and large-scale DNA purifica- tion. With the new breakthrough of CRIS- PR-CAS9 technology, OriGene has quickly become a leading genome editing company, providing various vectors and gene-disrup- tion kits for every human gene. 2. Protein Assay and Antibodies OriGene's 10,000 recombinant human proteins produced in human cells are of high value to researchers that are interested in authentic structure. Proteins with correct post-translational modifications (phosphory- lation, glycosylation, etc.) are crucial for biologically relevant structure and functional studies. They are also ideal for assay develop- ment, small molecule interaction screening, or as antigens for antibody production. Taking full advantage of the large collec- tion of human proteins, OriGene has cre- ated a monthly manufacturing capacity to produce over 300 TrueMAB monoclonal antibodies. Genomic Antibody Technology, a novel antibody development platform, is also employed by OriGene to create over 1,000 antibodies against difficult targets, including multispan membrane proteins and GPCR. Such highly specific antibodies di- rected against authentic human protein anti- gens are ideal for critical assay development, especially for Flow, IP, IF, IHC, ELISA, and functional assays. 3. Diagnostic Tests Anatomic Pathology for Oncology Bio- markers: To address the unresolved chal- lenges of antibody cross-reactivity, OriGene has created UltraMAB™, a new class of anti- bodies. Each UltraMAB has been rigorously tested on OriGene's proprietary high-density 10K protein lysate microarray to validate its mono-specificity against human protein antigens. This unmatched quality is crucial for antibody-based tests of IHC and/or flow cytometry. The launch and expansion of the UltraMAB collection have been greatly ap- preciated by leading diagnostic companies and antibody drug developers. Critical Reagents for IVD: With the ac- quisition of SDIX, OriGene enters the IVD market as a preferred supplier of bulk criti- cal reagents for many IVD test kits. The key products include Troponin, CRP, ALB, Strep A, and various calibrators. The accredited fa- cilities specialize in providing bulk antibody production (in vivo and in vitro) and custom formulation. Capabilities From the largest collections of full-length cDNA clones, to human-cell produced purified proteins, from TrueMAB and UltraMAB anti- bodies, to IVD antibodies, OriGene has evolved from a gene-based research toolbox to a unique antibody supplier. The decade-long dedication in creating the solid foundation of TrueORF Gold clone collection, TrueMAB, 10K pro- tein chip, UltraMAB, and Genomic Antibody Technology has positioned OriGene as an ir- replaceable company for both basic and clini- cal researchers. For more information, contact businessdev@origene.com. n